lirafugratinib (RLY-4008)
oral covalent FGFR2 inhibitor Ph. II for cholangiocarcinoma from rational design with MD simulations Cancer Discov., June 4, 2023 Relay Therapeutics Inc., Cambridge MA
Molecules of the Month - June 2023
oral covalent FGFR2 inhibitor Ph. II for cholangiocarcinoma from rational design with MD simulations Cancer Discov., June 4, 2023 Relay Therapeutics Inc., Cambridge MA
Molecules of the Month - June 2023